Lu-PSMA-617 Radioligand Treatment in Elderly Patients with Metastatic Castration-resistant Prostate Cancer: Therapeutic Efficacy and Safety Assessment.

Objective: This study aimed to evaluate the therapeutic efficacy and safety of Lutetium-Prostate Specific Membrane Antigen (Lu-PSMA-617) radioligand treatment (RLT) in metastatic castration-resistant prostate cancer (mCRPC) patients with aged older than 75 years.

Methods: A total of 37 patients with mCRPC aged older than 75 years treated with Lu- PSMA-617 were included in this study. Pre-therapy and post-therapy biochemical, metabolic, and clinical response results and Hb, TLC, platelet, serum creatinine and bilirubin levels were checked to evaluate the therapeutic efficacy and toxicity profile.

Ga-FAPI PET/CT as an Alternative to F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma.

Accurate staging of invasive lobular carcinoma (ILC), a subtype of breast cancer, is vital for effective clinical management. Although F-FDG PET/CT is a commonly used tool, its efficacy varies across different histologic subtypes. To mitigate this challenge, our investigation delves into the potential utility of Ga-fibroblast activation protein inhibitor (FAPI) PET/CT as an alternative for staging ILC, aiming to address a significant research gap using a more expansive patient cohort than the smaller samples commonly found in the existing literature.

Lutetium-177-PSMA-617 radioligand therapy in patients with high volume metastatic prostate cancer prior to chemotherapy and new generation androgen deprivation therapy: Clinical Experience.

Objective: We aimed to evaluate the efficacy oflutetium-177-prostate-specific membrane antigen-617 (Lu-PSMA-617) with the luteinizing hormone releasing hormone (LHRH) analogues in the first or in the second-line setting formetastatic castration sensitive patients and metastatic castration resistance after progression with LHRH analogues.

Subjects And Methods: Sixteen consecutive patients with high volume metastatic prostate cancer undergone Lu-PSMA-617 therapy who were refused chemotherapy and were unable to use new generation anti-androgen drugs because of unavailibility of reimbursement, were included in this retrospective study. Prostate specific antigen (PSA) response (>50% decrease), disease control rate (DCR: complete or partial response), progression-free survival (PFS) and overall survival (OS) were calculated to evaluate according to the clinicopathological features of the patients.

Comparison of Ga-FAPI PET/CT and FDG PET/CT Modalities in Gastrointestinal System Malignancies with Peritoneal Involvement.

Purpose: In this study, we aimed to investigate the utilization of Ga-FAPI PET/CT in comparison to FDG PET/CT to evaluate the peritoneal involvement of the gastrointestinal malignancies alongside primary lesions and other metastatic foci.

Procedures: A total of 37 patients with various gastrointestinal malignancies with accompanying peritoneal involvement who underwent Ga-FAPI PET/CT and FDG PET/CT imaging between September 2020 and June 2021 were included in this retrospective study. SUV values of Ga-FAPI and FDG were compared according to lesion locations.

Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience.

Objective: In this study, we aimed to compare [68Ga]FAPI PET/CT and [18F]FDG PET/CT imaging to detect lesions in multiple myeloma.

Methods: A total of 14 patients with multiple myeloma who underwent [68Ga]FAPI PET/CT and [18F]FDG PET/CT imaging were included in this retrospective study. SUV values of [68Ga]FAPI and [18F]FDG were compared according to lesion locations.